Pre-Eclampsia - Pipeline Review, H1 2016 - Product Image

Pre-Eclampsia - Pipeline Review, H1 2016

  • ID: 3691116
  • Report
  • 64 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • A1M Pharma AB
  • Glenveigh Medical, LLC
  • rEVO Biologics, Inc.
  • RTI International
  • VG Life Sciences, Inc.
  • MORE
Pre-Eclampsia - Pipeline Review, H1 2016

Summary

‘Pre-Eclampsia - Pipeline Review, H1 2016’, provides an overview of the Pre-Eclampsia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pre-Eclampsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pre-Eclampsia and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pre-Eclampsia
- The report reviews pipeline therapeutics for Pre-Eclampsia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Pre-Eclampsia therapeutics and enlists all their major and minor projects
- The report assesses Pre-Eclampsia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Pre-Eclampsia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Pre-Eclampsia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pre-Eclampsia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • A1M Pharma AB
  • Glenveigh Medical, LLC
  • rEVO Biologics, Inc.
  • RTI International
  • VG Life Sciences, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Pre-Eclampsia Overview

Therapeutics Development

Pipeline Products for Pre-Eclampsia - Overview

Pre-Eclampsia - Therapeutics under Development by Companies

Pre-Eclampsia - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Pre-Eclampsia - Products under Development by Companies

Pre-Eclampsia - Companies Involved in Therapeutics Development

A1M Pharma AB

Alnylam Pharmaceuticals, Inc.

Glenveigh Medical, LLC

Pluristem Therapeutics Inc.

rEVO Biologics, Inc.

RTI International

VG Life Sciences, Inc.

Pre-Eclampsia - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

A1M-001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ALN-AGT - Drug Profile

Product Description

Mechanism of Action

R&D Progress

antithrombin alfa (recombinant) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

digoxin immune fab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PLX-PAD - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Agonize Apelin Receptor for Pre-Eclampsia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Agonize CLR and RAMP Receptors for Pre-Eclampsia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

VG-1177 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Pre-Eclampsia - Recent Pipeline Updates

Pre-Eclampsia - Dormant Projects

Pre-Eclampsia - Product Development Milestones

Featured News & Press Releases

Jan 14, 2016: St. John Hospital Enrolling Patients in Phase 3 Trial for Early Onset Preeclampsia

Jan 06, 2016: New Peer Reviewed Article Describes Mechanism of Action of PLX-PAD in Ameliorating Preeclampsia and Indicates Their Superiority Over Other Cells

Dec 31, 2015: U.S. Food & Drug Administration Grants Orphan Drug Designation to Pluristem’s PLX-PAD Cells for Treatment of Severe Preeclampsia

Sep 24, 2015: New clinical trial at SLU treats preeclampsia in second-trimester pregnancies

Sep 12, 2014: Alnylam Broadens Pipeline with ALN-AGT, a Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen for the Treatment of Hypertensive Disorders of Pregnancy, Including Preeclampsia

Sep 10, 2014: Pluristem to Deliver Scientific Presentations at 3rd International Placenta Stem Cell Society Meeting

Jul 23, 2014: rEVO Biologics Announces Enrollment of First Patient in Phase 3 Trial of ATryn to Treat Early Onset Preeclampsia (PRESERVE-1)

Jul 08, 2014: Orphan Drug Designation Granted in Europe for A1M Pharma’s Treatment for Preeclampsia

Mar 31, 2014: rEVO Biologics Initiates PRESERVE-1 Phase 3 Clinical Trial for ATryn in Early-Onset Preeclampsia

Feb 25, 2014: rEVO Biologics Announces the Submission of an IND for ATryn in Preeclampsia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Pre-Eclampsia, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Pre-Eclampsia - Pipeline by A1M Pharma AB, H1 2016

Pre-Eclampsia - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016

Pre-Eclampsia - Pipeline by Glenveigh Medical, LLC, H1 2016

Pre-Eclampsia - Pipeline by Pluristem Therapeutics Inc., H1 2016

Pre-Eclampsia - Pipeline by rEVO Biologics, Inc., H1 2016

Pre-Eclampsia - Pipeline by RTI International, H1 2016

Pre-Eclampsia - Pipeline by VG Life Sciences, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pre-Eclampsia Therapeutics - Recent Pipeline Updates, H1 2016

Pre-Eclampsia - Dormant Projects, H1 2016

List of Figures

Number of Products under Development for Pre-Eclampsia, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Targets, H1 2016

Number of Products by Stage and Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
A1M Pharma AB
Alnylam Pharmaceuticals, Inc.
Glenveigh Medical, LLC
Pluristem Therapeutics Inc.
rEVO Biologics, Inc.
RTI International
VG Life Sciences, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll